Pfizer account plan
Developing innovative healthcare therapies
At a glance
Pfizer is a global biopharmaceutical company supplying about 200 countries: $62.6 billion FY2025 revenue and approximately 75,000 employees.
Pfizer Inc., headquartered in New York City, discovers, develops, manufactures and sells medicines and vaccines in oncology, internal medicine, vaccines, and inflammation and immunology, supplying approximately 200 countries and territories through 36 manufacturing plants. Products are sold mainly to wholesalers, with McKesson, Cencora and Cardinal Health taking 25%, 16% and 13% of 2025 revenues. FY2025 total revenues were $62.6 billion, down 2% as Paxlovid and Comirnaty fell, but up 6% operationally excluding those COVID-19 products; reported diluted EPS was $1.36 and adjusted diluted EPS $3.22. It had approximately 75,000 employees at December 31, 2025. Albert Bourla is Chairman and CEO.
Business units
Primary Care (Biopharma)
about 43% of FY2025 revenue ($26.8 billion)Eliquis ($7,961 million), the Prevnar family, Comirnaty, Abrysvo, Nurtec ODT/Vydura and Paxlovid. Revenue fell from $30.1 billion as Paxlovid dropped 59% and Comirnaty 20%. Eliquis grew 19% operationally in Q2 2026.
Specialty Care (Biopharma)
about 28% of FY2025 revenue ($17.5 billion)Rare disease led by the Vyndaqel family ($6,380 million, up 16% operationally, the largest growth driver), inflammation and immunology (Xeljanz, Cibinqo, Litfulo) and anti-infectives.
Oncology (Biopharma)
about 27% of FY2025 revenue ($16.8 billion)Ibrance, Xtandi, Padcev, Lorbrena, Adcetris and oncology biosimilars, much of it from the Seagen acquisition. Padcev grew 22% and Lorbrena 40% in 2025.
Global Hospital and Biosimilars (Biopharma)
$2.4 billion of H1 2026 revenueA division created on January 1, 2026 for off-patent sterile injectables and biosimilars such as Inflectra, Retacrit, Ruxience and Fragmin, everywhere except China and certain other international markets.
Pfizer CentreOne (PC1)
about 2% of FY2025 revenue ($1,338 million)Pfizer's contract development and manufacturing organization and specialty API supplier; revenue grew 15% operationally in 2025 and $373 million in Q2 2026. It now also holds the wind-down of Pfizer Ignite.
Strategic priorities
- Maximize key transactions
- Extract value from Seagen (about $1 billion of cost synergies by end-2026), Metsera (about $600 million) and Biohaven; legacy Seagen U.S. sales grew 21% in Q2 2026.
- Obesity
- Develop berobenatide, the monthly GLP-1 from Metsera, with 10 Phase 3 studies planned in 2026 and a first approval targeted in 2028, in a market Pfizer sizes at $150 billion.
- Post-2028 growth
- Aim for a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033, built on in-line growth products and 20 key potential new medicines and vaccines.
- Scale AI across the business
- Use AI in R&D, manufacturing, commercial and patient engagement, including more than 1,200 GPUs, with the ambition of an AI-native R&D organization.
- Cost savings
- Total expected net savings are about $9.7 billion through 2029, including cost realignment of about $6.7 billion and manufacturing optimization of about $3.0 billion.
Latest results
In Q2 2026 (quarter to June 28, 2026) revenues rose 3% to $15,034 million, up 5% operationally excluding Comirnaty and Paxlovid, led by Eliquis ($2,425 million, +19% operationally), Padcev (+23%) and Lorbrena (+37%). The reported result was a loss of $(0.04) per diluted share after $4.3 billion of impairments, mainly $3.8 billion for sigvotatug vedotin after its Phase 3 lung-cancer readout; adjusted diluted EPS was $0.77. H1 2026 revenues were $29,484 million, up 4%. Pfizer raised 2026 revenue guidance to $60.5-62.5 billion, with COVID-19 revenue cut to about $4 billion, and reaffirmed adjusted EPS of $2.80-3.00.
Investments and deals
- Metsera acquisition
- Acquired on November 13, 2025 for $65.60 per share plus a CVR of up to $20.65 per share, for total consideration of $8.0 billion.
- Innovent licensing deal
- A deal for 12 early-stage ADC and multi-specific cancer programs, with $650 million upfront and up to $9.85 billion in milestones, closed July 10, 2026.
- In-licensing from China
- 3SBio (oncology, including the PD-1xVEGF bispecific, a $1.35 billion charge) and YaoPharma (obesity, a $150 million charge) in 2025.
- Divestments
- The Haleon stake was sold for $6.3 billion in 2025 and the 11.7% ViiV stake exited for $1.875 billion on March 31, 2026.
- Manufacturing and capex
- About $2.5 billion of PP&E spending is expected in 2026; binding U.S. agreements on pricing and manufacturing investment set Pfizer's Section 232 tariff rate at zero until January 20, 2029.
Challenges and risks
- Loss of exclusivity
- A significant, accelerating revenue reduction is expected from 2026 through 2030, about $1.1 billion in 2026; Eliquis U.S. generics are permitted from April 1, 2028.
- IRA price setting
- The IRA Maximum Fair Price applies to Eliquis from January 1, 2026 and to Ibrance and Xtandi in 2027.
- COVID-19 product decline
- Paxlovid fell 95% and Comirnaty 34% in Q2 2026; 2026 COVID-19 revenue is now expected at about $4 billion.
- Pipeline setbacks
- Sigvotatug vedotin missed its Phase 3 overall-survival endpoint and Oxbryta was written down, driving $4.3 billion of Q2 2026 impairments.
- Leverage and product concentration
- Leverage was 2.7 times and is expected to stay there or modestly higher through the patent-expiry period; 12 products above $1 billion made 65% of 2025 revenues.
What leadership says
“clear line of sight to our aim of delivering a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033”
“For the first time, we have shown that the GLP-1 receptor agonist peptides can be administered monthly”
“We didn't just cut cost, what we did is we improved productivity”
“our focus is maintaining our dividend at the moment and growing our dividend over time.”
Where a supplier can help
- AI for R&D and manufacturing
- Tied to the scale-AI priority: AI infrastructure, data platforms and use cases in trial design, manufacturing yield and field-force targeting.
- Clinical trial capacity for obesity
- Tied to the obesity priority and 10 Phase 3 studies planned in 2026: CRO, patient recruitment and trial technology services.
- Cost and productivity programs
- Tied to the $9.7 billion savings target: automation and simplification in commercial, R&D and enabling functions.
- U.S. manufacturing investment
- Tied to the tariff agreement and manufacturing optimization: equipment, engineering and network restructuring services.
- Launch commercialization
- Tied to the loss-of-exclusivity challenge: omnichannel marketing and analytics that accelerate launched and acquired products such as Padcev and Nurtec.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Pfizer?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- Pfizer is a research-based global biopharmaceutical company headquartered in New York City, supplying medicines and vaccines to approximately 200 countries and territories, with approximately 75,000 employees at December 31, 2025 and 36 manufacturing plants run by Pfizer Global Supply.
- FY2025 total revenues were $62.6 billion, down 2% (operationally down 2%), driven by Paxlovid (down $3.3 billion) and Comirnaty (down $1.1 billion); excluding those two COVID-19 products, revenues grew 6% operationally. Reported diluted EPS was $1.36 and Adjusted diluted EPS (non-GAAP) $3.22; operating cash flow $11.7 billion.
- Biopharma is the only reportable segment ($61.2 billion revenue), split by customer group into Primary Care ($26.8 billion), Specialty Care ($17.5 billion) and Oncology ($16.8 billion); PC1 (contract manufacturing and APIs, $1.3 billion) and the discontinued Pfizer Ignite sit outside it. A new Global Hospital and Biosimilars division started on January 1, 2026.
- Concentration: 12 products above $1 billion made 65% of revenues; Eliquis alone was 13% ($8.0 billion). Growth came from the Vyndaqel family ($6.4 billion, +16% operationally), Padcev (+22%), Lorbrena (+40%) and Abrysvo (+36%). International operations were 41% of revenue; McKesson, Cencora and Cardinal Health took 25%, 16% and 13%.
- 2026 key priorities: maximize value of key transactions (Metsera, acquired November 2025 for $65.60/share plus a CVR; Seagen, acquired December 2023 for $44.2 billion), deliver critical R&D milestones, invest to maximize post-2028 growth, and scale AI across the business.
- Patent cliff: a significant reduction of revenue from exclusivity expiries is expected in 2026 through 2030, with a $1.5 billion impact expected in 2026; Eliquis U.S. generics are permitted from April 1, 2028. IRA price setting hit Eliquis from January 1, 2026, with Ibrance and Xtandi in 2027.
- Cost programs: the cost realignment program is to deliver about $5.7 billion of net savings through 2026 ($5.1 billion achieved through 2025); the first phase of the Manufacturing Optimization Program targets about $1.5 billion by end-2027. Seagen synergies of about $1 billion and Metsera synergies of about $600 million are expected by end-2026.
- A September 2025 agreement with the Trump Administration on drug pricing (including TrumpRx.gov) gives a three-year grace period from Section 232 tariffs provided Pfizer further invests in U.S. manufacturing. Capital allocation: maintain and grow the dividend ($0.43 per quarter), no buybacks in 2025, de-lever; Haleon stake sold for $6.3 billion and ViiV stake agreed for $1.9 billion.
- Quarterly Report on Form 10-Q for the second quarter of 2026
- Q2 2026 (quarter to June 28, 2026) revenues were $15.0 billion, up 3% (1% operationally; 5% operationally excluding Comirnaty and Paxlovid). H1 2026 revenues were $29.5 billion, up 4% (6% operationally excluding COVID-19 products).
- Q2 reported diluted loss per share was $(0.04) after $4.3 billion of asset impairments, mainly $3.8 billion for sigvotatug vedotin after its Phase 3 lung-cancer readout. Adjusted diluted EPS (non-GAAP) was $0.77.
- Growth drivers in Q2: Eliquis $2,425 million (+19% operationally, U.S. +25%), Padcev $667 million (+23%), the Vyndaqel family $1,762 million (+8%) and Lorbrena $354 million (+37%). Comirnaty fell 34% and Paxlovid 95% to $21 million; the Prevnar family fell 4%.
- From 2026 Pfizer reports two operating segments, Biopharma and PC1. Biopharma has a new Global Hospital and Biosimilars division ($2.4 billion of H1 revenue) alongside U.S. Commercial ($15.6 billion) and International Commercial ($10.8 billion).
- New cost targets announced in Q3 2026: a further $1.0 billion of SI&A savings in 2027-2029, raising cost realignment to about $6.7 billion through 2029; and a new manufacturing optimization phase worth about $1.5 billion, raising that program to about $3.0 billion through 2029 at about $4.0 billion of one-time cost.
- Deals: a licensing pact with China's Innovent for 12 early-stage ADC and multi-specific cancer programs ($650 million upfront, up to $9.85 billion in milestones) closed July 10, 2026. The 11.7% ViiV stake was exited for $1.875 billion.
- Trade and pricing: binding agreements with the U.S. government set Pfizer's Section 232 pharma tariff rate at zero until January 20, 2029. The expected 2026 revenue hit from loss of exclusivity is now about $1.1 billion. Leverage is expected to stay around current levels, or modestly higher, through the patent-expiry period.
- Second quarter 2026 earnings conference call (transcript)
- CEO Albert Bourla called Q2 2026 "another strong quarter of execution": revenues of $15 billion (+1% operationally, +5% excluding COVID-19 products) and adjusted diluted EPS of $0.77 both beat expectations. He said this was the ninth revenue beat in 10 quarters.
- Guidance: 2026 revenue was raised to $60.5-62.5 billion, with COVID-19 revenue cut to about $4 billion from $5 billion. Adjusted EPS guidance of $2.80-3.00 was reaffirmed, absorbing about $0.10 from the $650 million Innovent charge. Adjusted gross margin is expected in the mid-70s.
- Leadership change: CFO David Denton is leaving, and Cecile Guegan becomes interim CFO.
- Launched and acquired products made $3.2 billion in the quarter, up 18% operationally (27% excluding one-time 2025 items). Legacy Seagen U.S. sales grew 21%.
- Cost savings: a new $2.5 billion of net savings for 2027-2029 takes total expected net savings to about $9.7 billion through 2029.
- Capital: business development (BD) capacity after Innovent is about $6 billion and leverage is 2.7 times. Bourla said "the dividend will be maintained" and will grow again after the loss-of-exclusivity (LOE) period.
- Long-term ambition: a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033, built on in-line growth products and 20 key potential new medicines and vaccines.
- Obesity (Metsera): berobenatide is to be a monthly GLP-1, targeting first approval in 2028, with 10 Phase 3 studies planned in 2026. Pfizer sizes the obesity market at $150 billion.
- Oncology: Padcev's indication now spans the disease continuum. Mevrometostat's first Phase 3 readout (MEVPRO-1) is expected in Q4. The PD-1xVEGF bispecific 4404 is in two Phase 3 trials. Sigvotatug vedotin's Phase 3 missed its endpoint; with Oxbryta it drove $4.3 billion of non-cash impairments in the quarter.
- Fourth quarter and full year 2025 earnings conference call (transcript)
- 2025 results: revenues of $62.6 billion (-2% operationally, +6% excluding COVID-19 products); reported diluted EPS $1.36; adjusted diluted EPS $3.22 (prior year: $3.11). Adjusted gross margin expanded to 76%, and $9.8 billion was returned as dividends.
- Q4 2025: revenues of $17.6 billion (-3% operationally), with COVID products down about 40% and non-COVID products up 9% operationally. Adjusted EPS was $0.66 against a GAAP loss of $0.29 after about $4.4 billion of impairments.
- 2026 guidance was reaffirmed: revenues of $59.5-62.5 billion and adjusted EPS of $2.80-3.00. It assumes about $5 billion of COVID revenue, about $1.5 billion of loss-of-exclusivity (LOE) erosion, about 4% operational growth at the midpoint excluding COVID and LOE products, and about $11 billion of R&D.
- Four 2026 priorities: maximize key transactions (Seagen, Metsera, Biohaven); deliver R&D milestones (about 20 pivotal studies, 8 key readouts); invest for post-2028 growth; and scale AI, including more than 1,200 GPUs.
- Obesity: VESPER-3 showed monthly '3944 (the Metsera GLP-1) giving 10% and 12.3% placebo-adjusted weight loss at week 28, with first approvals targeted for 2028. Pfizer sizes the market at $150 billion.
- Capital: 2025 included $10.4 billion of internal R&D and about $8.8 billion of business development. Leverage is near 2.7 times and BD capacity about $7 billion including ViiV proceeds. Management's priority is to maintain the dividend, then grow it.
- Cost: Pfizer is on track for most of $7.2 billion of total net savings by end-2026, including the $5.7 billion cost realignment and $1.5 billion of manufacturing savings by 2027.
Questions about Pfizer
What does Pfizer do?
Pfizer is a research-based biopharmaceutical company that develops, manufactures and sells medicines and vaccines in oncology, internal medicine, vaccines, and inflammation and immunology in approximately 200 countries and territories.
What is Pfizer's revenue?
FY2025 total revenues were $62.6 billion, down 2%. 2026 guidance is $60.5-62.5 billion.
How many employees does Pfizer have?
Approximately 75,000 employees at December 31, 2025.
Who leads Pfizer?
Albert Bourla is Chairman and CEO. CFO David Denton is leaving and Cecile Guegan is interim CFO; Chris Boshoff is Chief Scientific Officer.
What is Pfizer's strategy?
Maximize the Seagen, Metsera and Biohaven deals, deliver R&D milestones especially in obesity and oncology, invest for growth after 2028 patent expiries, and scale AI while cutting about $9.7 billion of costs through 2029.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)